ÂÜÀòÂÒÂ×

Emmanuel Monnet has a diverse work experience spanning over two decades. Emmanuel is currently employed at Sobi - Swedish Orphan Biovitrum AB (publ) as the Head of Clinical Science since March 2023. Prior to that, they held the position of Head of Medical Affairs and Clinical Sciences, emapalumab, from January to March 2023. From 2019 to 2023, they served as a Sr Clinical Science Leader at the same company. Before joining Sobi, Emmanuel worked at NovImmune as a Sr Clinical Science Leader from 2012 to 2019. Emmanuel also held the role of Director, Biomarker Strategy, Clinical Development at Merck Serono from 2008 to 2012. Earlier in their career, they were a Sr Scientist, Human Genetics, Exploratory Medicine at Serono International from 2004 to 2008. Emmanuel started their professional journey at Sanofi-Synthelabo as a Senior Research Investigator & Research Investigator, focusing on Pharmacogenetics, Metabolism, and Pharmacokinetics, from 2000 to 2004. Emmanuel pursued a PhD at INSERM from 1997 to 2000 and started their research career as a Research Fellow at Ciba-Geigy in 1996.

Emmanuel Monnet holds a Ph.D. in Human Biology, Pharmacology, and Haematology from the University Paris 7, Diderot. Emmanuel also completed the Biopharma program at the London Business School in 2012. Additionally, they have pursued studies in the field of Genetics of complex diseases at the Duke University School of Medicine and has attended KU Leuven. Emmanuel obtained a DEA degree from Université Paris Cité. Emmanuel Monnet has also obtained certification in Orphan Drugs Clinical Trials from Symmetric Training in 2021.